1. Home
  2. MYGN vs OIO Comparison

MYGN vs OIO Comparison

Compare MYGN & OIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Myriad Genetics Inc.

MYGN

Myriad Genetics Inc.

N/A

Current Price

$5.44

Market Cap

523.7M

Sector

Health Care

ML Signal

N/A

Logo OIO Group Ordinary Shares

OIO

OIO Group Ordinary Shares

N/A

Current Price

$1.59

Market Cap

556.8M

Sector

Utilities

ML Signal

N/A

Company Overview

Basic Information
Metric
MYGN
OIO
Founded
1991
1999
Country
United States
Singapore
Employees
2700
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Environmental Services
Sector
Health Care
Utilities
Exchange
Nasdaq
Nasdaq
Market Cap
523.7M
556.8M
IPO Year
1996
2022

Fundamental Metrics

Financial Performance
Metric
MYGN
OIO
Price
$5.44
$1.59
Analyst Decision
Hold
Analyst Count
9
0
Target Price
★ $5.90
N/A
AVG Volume (30 Days)
★ 1.7M
101.3K
Earning Date
11-04-2026
12-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $771,400,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 2.33
N/A
52 Week Low
$2.74
$1.36
52 Week High
$8.09
$7.50

Technical Indicators

Market Signals
Indicator
MYGN
OIO
Relative Strength Index (RSI) 46.99 38.63
Support Level $4.19 $1.58
Resistance Level $5.52 $2.07
Average True Range (ATR) 0.30 0.15
MACD -0.13 -0.02
Stochastic Oscillator 0.00 40.43

Price Performance

Historical Comparison
MYGN
OIO

About MYGN Myriad Genetics Inc.

Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.

About OIO OIO Group Ordinary Shares

OIO Group operates as an investment and development platform operating through its subsidiary, ESA, which is a waste management, treatment, and recycling company involved in the collection and recycling of hazardous and non-hazardous industrial waste from customers such as pharmaceutical, semiconductor, petrochemical, and electroplating companies. ESA currently has two revenue streams, from: (i) services income which is mainly comprised of the fees it charges its customers for waste collection and disposal services, which fees are similar to those charged by ESA's competitors, and (ii) the sales and trading of ESA's circular products that are made and processed from the recycled waste collected from its customers with respect to its waste collection and disposal services.

Share on Social Networks: